PI 3-kinase p110δ Lentiviral Activation Particles (m): sc-422232-LAC
- Target species: mouse
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- PI 3-kinase p110δ Lentiviral Activation Particles (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- PI 3-kinase p110δ Lentiviral Activation Particles (m) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by PI 3-kinase p110δ Lentiviral Activation Plasmid (m) and PI 3-kinase p110δ Lentiviral Activation Plasmid (m2) target distinct regulatory regions of the Pik3cd promoter. One or both designs may be available
- Following transfection, gene activation efficiency can be assayed by WB, IF or IHC using antibody: PI 3-kinase p110δ Antibody (A-8): sc-55589
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PI 3-kinase p110δ Lentiviral Activation Particles (m) | sc-422232-LAC | 200 µl | $455.00 |
Pik3cd encodes the catalytic p110δ subunit of class I phosphoinositide 3-kinase, a key enzyme that phosphorylates PIP2 to generate PIP3 and propagate PI3K–AKT–mTOR signaling. In mouse immune and hematopoietic lineages, p110δ helps couple antigen receptor and cytokine receptor inputs to downstream control of cell survival, proliferation, metabolism, and chemotaxis, including effects on NF-κB and FOXO-dependent transcriptional programs. Altered Pik3cd activity is widely studied for its impact on lymphocyte activation, inflammatory signaling, and immune homeostasis, with relevance to models of immune dysregulation and oncogenic pathway rewiring. These functions make Pik3cd a useful node for dissecting signal transduction networks that shape immune cell fate decisions.
PI 3-kinase p110δ Lentiviral Activation Particles (m) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient Pik3cd upregulation across a broader range of human cell types.
PI 3-kinase p110δ Lentiviral Activation Particles (m) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the Pik3cd transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous PI 3-kinase p110δ expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native Pik3cd genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.